Medizinische Hochschule Hannover (Mhh)

Medizinische Hochschule Hannover (MHH Hannover), a foreign government research institution based in Hannover, Germany, operates as a sub-recipient on federal research grants in the biomedical sciences, with no direct federal contracting footprint. The entity is a state-controlled institution of higher learning under German government ownership and receives federal research funding exclusively through sub-awards on grants administered by U.S. universities and research centers under National Institutes of Health (NIH) grants.

MHH's federal footprint is modest and grant-centric. Across fourteen awards in the source data spanning 2008 to March 2026, MHH serves in a sub-recipient role on eleven grants (79% of awards) and as a prime grant recipient on three awards (21%). The combined potential value across all awards totals $318 thousand, though combined obligated dollars reach $2.9 million — a signal that MHH has drawn down substantial funding against smaller nominal award values. The entity has worked with five distinct federal agencies, all components of the Department of Health and Human Services. The National Institute of Allergy and Infectious Diseases accounts for five awards, the National Heart Lung and Blood Institute for three awards, and the National Institute of Neurological Disorders and Stroke and National Institute of Mental Health for two awards each, with the Food and Drug Administration contributing one award valued at $238 thousand.

Recent work demonstrates MHH's role in advanced biomedical research and supporting functions. MHH holds a March 2026 prime grant from the National Heart Lung and Blood Institute (ultimate completion March 2027) investigating the growth factor meteorin-like and its receptor KIT in heart failure pathogenesis. As a sub-recipient, MHH has provided expertise in quantitative lung MRI imaging analysis and data extraction on Columbia University-led grants (January and July 2025 sub-awards), supported genome sequencing and ChIP-Seq library construction on a Cornell University-led project (July 2024), and contributed viral immunology and epitranscriptomics research support on multiple New York University-led NIH grants spanning 2023 to 2024. MHH also participated as a sub-recipient on Fred Hutchinson Cancer Center-led grants developing dual AAV vectors for in vivo B cell transduction (awards in October 2024 and August 2025) and on a University of Minnesota intracranial auditory nerve implant development project (December 2022).

Award activity has accelerated modestly — two awards in 2022, one in 2023, five in 2024, three in 2025, and one in 2026. Only one award faces completion within the next twenty-four months, indicating limited near-term recompete exposure. MHH's role is anchored to collaborative research partnerships where its institutional expertise in medical imaging, molecular virology, and genomic analysis serves as a specialized research capability embedded within larger NIH-funded consortia led by U.S. research universities.